Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating expenses
Research and development	$ 13,517	$ 14,602
Selling, general and administrative	29,259	8,472
Change in fair value of contingent consideration	2,967	401
Total operating expenses	45,743	23,475
Operating loss	(45,743)	(23,475)
Other income (expense), net
Interest income, net	3,331	2,077
Interest expense	(1,361)
Total other income (expense), net	1,970	2,077
Net loss	(43,773)	(21,398)
Other comprehensive income (loss)
Net unrealized loss on marketable securities	(139)	(105)
Foreign currency translation adjustment	4	(1)
Total comprehensive loss	$ (43,908)	$ (21,504)
Net loss per common share basic	$ (0.95)	$ (0.59)
Net loss per common share diluted	$ (0.95)	$ (0.59)
Weighted-average common shares outstanding used to calculate basic net loss per common share	46,178,793	36,208,371
Weighted-average common shares outstanding used to calculate diluted net loss per common share	46,178,793	36,208,371